Home  /  Resource Library  /  Minimal residual disease (MRD) guided venetoclax consolidation following fixed duration combination treatment in previously untreated patients with chronic lymphocytic leukemia (CLL) Latest updates from the phase II HOVON 139 GiVe trial

Minimal residual disease (MRD) guided venetoclax consolidation following fixed duration combination treatment in previously untreated patients with chronic lymphocytic leukemia (CLL) Latest updates from the phase II HOVON 139 GiVe trial

cll, chronic lymphocytic, venetoclax, venclexta, venclyxto, obinutuzimab, gazyva, gazyvaro, treatment, survival, first line, front line, side effect, safety, adverse event, toxicity, minimal residual disease, mrd